Pitavastatin (pitavastatin calcium) NDC 51407-958

NDC codes

FDA NDC Directory

Product NDC (as listed)51407-958Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51407-0958Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51407-958-90	51407095890	90 TABLET in 1 BOTTLE (51407-958-90)Marketed from Dec 26, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pitavastatin
Generic name (nonproprietary): pitavastatin calcium
Active ingredients: Pitavastatin calcium — 4 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Golden State Medical Supply, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205955
Marketing start: Feb 3, 2017
Listing expires: Dec 31, 2027
Other FDA classes: Hydroxymethylglutaryl-CoA Reductase Inhibitors (Mechanism)
Identifiers: Product ID 51407-958_547b572f-9501-b0ca-e063-6394a90a539aSPL ID 547b572f-9501-b0ca-e063-6394a90a539aSPL set ID 2d5a1b78-4aa6-537b-e063-6394a90a522fRxCUI 861643, 861648, 861652UNII IYD54XEG3W
Pharmacologic class: HMG-CoA Reductase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451407095890 followed by a unit qualifier and the quantity

Package 51407-0958-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 17, 2026.

Indications (excerpt from the label)

Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). Pitavastatin tablets is a HMG-CoA reductase inhibitor (statin) indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: ( 1 ) Adults with primary hyperlipidemia Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 205955

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 205955
Product	Strength	Form · route	Labeler	Product NDC
Pitavastatinpitavastatin calcium	Pitavastatin calcium 4 mg/1	TabletOral	Upsher-Smith Laboratories, LLC	0832-6050
Pitavastatinpitavastatin calcium	Pitavastatin calcium 1 mg/1	TabletOral	Upsher-Smith Laboratories, LLC	0832-6048
Pitavastatinpitavastatin calcium	Pitavastatin calcium 2 mg/1	TabletOral	Upsher-Smith Laboratories, LLC	0832-6049
Pitavastatinpitavastatin calcium	Pitavastatin calcium 2 mg/1	TabletOral	Golden State Medical Supply, Inc.	51407-957
Pitavastatinpitavastatin calcium	Pitavastatin calcium 1 mg/1	TabletOral	Golden State Medical Supply, Inc.	51407-956